Close Menu

NEW YORK – The Association for Molecular Pathology (AMP) on Thursday released the preliminary results of its April SARS-CoV-2 testing survey for clinical laboratories, showing that while labs recognize the need to increase diagnostic testing capacity, a significant portion of them have experienced interruptions in their supply chains that have slowed down their ability to offer efficient testing programs to patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.